Skip to main content

Table 2 Univariate analysis results of progression-free survival in in 97 locally advanced esophageal squamous cell carcinoma patients who received curative concurrent chemoradiotherapy

From: The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy

Characteristics No. of patients Median PFS (months) P value
Age
  < 60 years 64 (66%) 15.6 0.044a
  ≥ 60 years 33 (34%) 11.5  
T status
 1 + 2 15 (16%) 19.1 0.35
 3 + 4 82 (84%) 11.9  
N status
 0 + 1 32 (33%) 20.3 0.38
 2 + 3 65 (67%) 11.9  
Stage
 II + IIIA + IIIB 31 (32%) 16.5 0.93
 IIIC 66 (68%) 11.5  
Grade
 1 + 2 71 (73%) 13.3 0.49
 3 26 (27%) 14.0  
Location
 Upper 40 (41%) 14.6 0.76
 Middle + Lower 57 (59%) 12.3  
VEGF Day 0 (Mean: 176 pg/mL)
  < 80 33 (34%) 14.2 0.20
  > 80 64 (66%) 13.3  
VEGF Day 5 (Mean: 163 pg/mL)    
  < 80 33 (34%) 18.2 0.39
  > 80 64 (66%) 11.9  
VEGF Day 28 (Mean: 195 pg/mL)
  < 80 29 (30%) 20.1 0.029a
  > 80 68 (70%) 11.5  
VEGF Day 5/Day 0 ratio
  < 1 52 (54%) 15.0 0.46
  > 1 45 (46%) 10.2  
VEGF Day 28/Day 0 ratio
  < 1 39 (40%) 16.3 0.55
  > 1 58 (60%) 11.5  
VEGF Day 28/Day 5 ratio
  < 1 45 (46%) 18.5 0.029a
  > 1 52 (54%) 8.2  
  1. PFS progression-free survival; VEGF vascular endothelial growth factor; HR hazard ratio; CI confidence interval
  2. aStatistically significant